News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
349,680 Results
Type
Article (21416)
Company Profile (137)
Press Release (328103)
Multimedia
Podcasts (124)
Webinars (20)
Section
Business (106111)
Career Advice (899)
Deals (18733)
Drug Delivery (121)
Drug Development (51156)
Employer Resources (80)
FDA (7897)
Job Trends (7852)
News (187352)
Policy (17503)
Tag
2027 BioCapital Elite (1)
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (749)
Accelerated approval (28)
Adcomms (25)
Allergies (107)
Alliances (27981)
ALS (109)
Alzheimer's disease (847)
Antibody-drug conjugate (ADC) (277)
Approvals (8154)
Artificial intelligence (342)
Autoimmune disease (140)
Automation (21)
Bankruptcy (179)
Best Places to Work (5557)
BIOSECURE Act (14)
Biosimilars (197)
Biotechnology (59)
Bladder cancer (86)
Brain cancer (44)
Breast cancer (304)
Cancer (2730)
Cardiovascular disease (281)
Career advice (752)
Career pathing (28)
CAR-T (122)
CDC (20)
Cell therapy (330)
Cervical cancer (17)
Clinical research (45470)
Collaboration (1211)
Company closure (2)
Compensation (429)
Complete response letters (66)
COVID-19 (1166)
CRISPR (56)
C-suite (700)
Cystic fibrosis (92)
Data (4011)
Decentralized trials (3)
Denatured (28)
Depression (94)
Dermatology (41)
Diabetes (285)
Diagnostics (1943)
Digital health (20)
Diversity (9)
Diversity, equity & inclusion (22)
Drug discovery (216)
Drug pricing (215)
Drug shortages (36)
Duchenne muscular dystrophy (165)
Earnings (41603)
Editorial (52)
Employer branding (10)
Employer resources (79)
Events (51732)
Executive appointments (686)
FDA (9757)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (6)
Frontotemporal dementia (9)
Funding (773)
Gene editing (102)
Generative AI (40)
Gene therapy (314)
GLP-1 (890)
Government (2057)
Grass and pollen (4)
Guidances (213)
Healthcare (5966)
HIV (40)
Huntington's disease (29)
IgA nephropathy (70)
Immunology and inflammation (201)
Immuno-oncology (51)
Indications (117)
Infectious disease (1339)
Inflammatory bowel disease (135)
Inflation Reduction Act (12)
Influenza (57)
Intellectual property (154)
Interviews (121)
IPO (7438)
IRA (54)
Job creations (2446)
Job search strategy (655)
JPM (55)
Kidney cancer (12)
Labor market (68)
Layoffs (350)
Leadership (33)
Legal (4159)
Liver cancer (39)
Longevity (12)
Lung cancer (383)
Lymphoma (236)
Machine learning (22)
Management (31)
Manufacturing (651)
MASH (122)
Medical device (2034)
Medtech (2049)
Mergers & acquisitions (11887)
Metabolic disorders (1029)
mRNA (100)
Multiple sclerosis (119)
NASH (21)
Neurodegenerative disease (198)
Neuropsychiatric disorders (88)
Neuroscience (1723)
Neurotech (1)
NextGen: Class of 2026 (2367)
Non-profit (922)
Now hiring (56)
Obesity (599)
Opinion (246)
Ovarian cancer (87)
Pain (178)
Pancreatic cancer (119)
Parkinson's disease (199)
Partnered (18)
Patents (329)
Patient recruitment (341)
Peanut (22)
People (34879)
Pharmaceutical (73)
Pharmacy benefit managers (36)
Phase 1 (14348)
Phase 2 (19183)
Phase 3 (15398)
Pipeline (4392)
Policy (254)
Postmarket research (1621)
Preclinical (5029)
Press Release (29)
Prostate cancer (157)
Psychedelics (33)
Radiopharmaceuticals (206)
Rare diseases (657)
Real estate (3212)
Recruiting (34)
Regulatory (14195)
Reports (26)
Research institute (844)
Resumes & cover letters (143)
Rett syndrome (11)
RNA editing (14)
RSV (50)
Schizophrenia (145)
Series A (150)
Series B (94)
Service/supplier (7)
Sickle cell disease (73)
Special edition (22)
Spinal muscular atrophy (125)
Sponsored (20)
Startups (2053)
State (2)
Stomach cancer (13)
Supply chain (90)
Tariffs (97)
The Weekly (93)
Vaccines (446)
Venture capital (81)
Weight loss (434)
Women's health (59)
Worklife (10)
Date
Last 7 days (373)
Last 30 days (1293)
Last 365 days (15213)
2026 (5291)
2025 (15481)
2024 (17677)
2023 (19668)
2022 (25875)
2021 (26644)
2020 (24881)
2019 (20061)
2018 (15593)
2017 (17259)
2016 (16208)
2015 (18813)
2014 (14794)
2013 (12555)
2012 (13487)
2011 (13820)
2010 (12742)
Location
Africa (419)
Alabama (46)
Alaska (1)
Arizona (100)
Arkansas (9)
Asia (26212)
Australia (3385)
California (5489)
Canada (2059)
China (895)
Colorado (226)
Connecticut (222)
Delaware (218)
Europe (54194)
Florida (962)
Georgia (111)
Hawaii (2)
Idaho (19)
Illinois (524)
India (70)
Indiana (336)
Iowa (5)
Japan (393)
Kansas (86)
Kentucky (33)
Louisiana (9)
Maine (4)
Maryland (664)
Massachusetts (4382)
Michigan (71)
Minnesota (274)
Mississippi (3)
Missouri (46)
Montana (13)
Nebraska (15)
Nevada (40)
New Hampshire (11)
New Jersey (2126)
New Mexico (21)
New York (1513)
North Carolina (891)
North Dakota (2)
Northern California (2627)
Ohio (149)
Oklahoma (8)
Oregon (23)
Pennsylvania (1210)
Puerto Rico (25)
Rhode Island (29)
South America (618)
South Carolina (13)
South Dakota (1)
Southern California (2343)
Tennessee (76)
Texas (753)
United States (20709)
Utah (103)
Virginia (214)
Washington D.C. (60)
Washington State (433)
West Virginia (1)
Wisconsin (59)
Wyoming (1)
349,680 Results for "verona pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Merck Completes Acquisition of Verona Pharma
October 8, 2025
·
8 min read
Mergers & acquisitions
Merck To Buy Terns, ‘Unprecedented’ Leukemia Drug for $6.7B as Keytruda Cliff Looms
Merck’s acquisition of Terns Pharmaceuticals follows other big-ticket purchases, including of Verona Pharma and Cidara Therapeutics, as the pharma prepares for the impending expiration of its blockbuster’s patents.
March 25, 2026
·
3 min read
·
Tristan Manalac
Press Releases
Shareholders of Verona Pharma Approve Proposed Acquisition by Merck
September 25, 2025
·
7 min read
Earnings
On steadier ground, pharma heads into Q1 earnings with deals top of mind
During the pharma earnings season, which begins on Tuesday, Novo Nordisk will report the first revenue numbers from an oral GLP-1 medicine, while other companies are expected to address the FDA, drug pricing and Trump’s new tariffs.
April 14, 2026
·
5 min read
·
Annalee Armstrong
Press Releases
Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025
September 16, 2025
·
4 min read
FDA
Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces the US Food and Drug Administration (“FDA”) approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.
June 26, 2024
·
10 min read
Earnings
J&J Reigns as Top Pharma by Revenue While Lilly Leapfrogs on Strong Obesity Sales
While Johnson & Johnson retains the top revenue rank across the major pharma companies, Eli Lilly last year established itself as the clear leader in the obesity market, in the process capturing investors’ attention and enthusiasm.
March 18, 2026
·
8 min read
·
Tristan Manalac
Press Releases
Verona Pharma Announces June 2025 Investor Conference Participation
May 21, 2025
·
1 min read
Government
RFK Jr. defends Makary, claims pharma ‘owns’ Congress and media
The pharma industry “own Congress, they own the media,” Health Secretary Robert F. Kennedy, Jr. told lawmakers by way of explaining the bad press against FDA Commissioner Marty Makary following the second rejection of Replimune’s advanced melanoma drug.
April 17, 2026
·
2 min read
·
Tristan Manalac
Bio NC
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
Verona Pharma plc, announces it and its wholly-owned subsidiary, Verona Pharma, Inc., have entered into strategic financing agreements providing access to up to $650 million from funds managed by Oaktree Capital Management, L.P. and OMERS Life Sciences.
May 9, 2024
·
10 min read
1 of 34,968
Next
